TIDES CDMO Services
Porton TIDES CDMO Services Platform has established multiple R&D centers and GMP production bases in Shanghai and Chongqing, China, providing end-to-end integrated API and Drug Product CDMO solutions for peptide and oligonucleotide products to global pharmaceutical companies and new drug R&D organizations, supporting different development stages from preclinical to commercial launch. Porton’s CDMO services cover process development & optimization, toxicology batch and clinical-stage sample production, structural characterization, formulation development and DP manufacturing, analytical method development and validation, in-process control and product release testing, ICH-compliant stability studies, as well as global new drug filing and other one-stop-shop CMC services. Porton is committed to enabling earlier access to good medicines.
100+
Global Customers
~30
IND/NDA Filling
50+
Experienced Scientists
Our Services
Peptides
Linear Peptides
Monocyclic & Multicyclic Peptides
Peptides with Special Sequences and Modified Functionalities
Unnatural Amino Acids and Peptide Fragment Intermediates
Oligonucleotides
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Drug Delivery Materials
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Linear Peptides
Monocyclic & Multicyclic Peptides
Peptides with Special Sequences and Modified Functionalities
Unnatural Amino Acids and Peptide Fragment Intermediates
Molecular Type
-
Linear Peptides (< 65 AA)
-
Monocyclic & Multicyclic Peptides with Linkages of
- Disulfides
- Amides
- Thioethers
-
RCM, Click, etc.
-
Peptides with Special Sequences and Modified Functionalities
- Peptides with Multiple Free Cys
- N-alkyl-rich Peptides
- Unnatural Amino Acids and Peptide Fragment Intermediates
- Key RSMs and Intermediates
- ADC Drug-Linker and PDC (OEB 5)
Technology
- Solid/Liquid/Hybrid Strategies Synthetic Solutions
- Combinate Downstream Technologies with Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Pre-formulation Development
- Comprehensive Analysis and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- Full Time Employee (FTE)
- Fee for Service (FFS)
ASO, siRNA
PMO
Aptamer
sgRNA
Oligo Modifications
Molecular Type
- 16~100 mer Oligonucleotides and Derivatives
- Modified Nucleotides
- Oligonucleotide Conjugates
- Custom Monomer
- Custom Galnac Derivatives
Technology
- Solid Phase Oligonucleotide Synthesis Technology Platform
- Ion Exchange, Ultrafiltration, Freeze-drying, and Other Purification and Post-processing Technologies
- Nucleic Acid Modification and Routine Injection Preparation Research and Development Capability (Including LNP)
- Comprehensive Analysis and Quality Research
Service Scope
- mg to g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Manufacturing (non-GMP and GMP)
- Formulation Development and GMP Manufacturing
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
- FTE (Full-Time Equivalent)
- FFS (Fee for Service)
Ionizable Lipids/Cationic Lipids
Polymers for Drug Delivery
Complex/Conjugate Polysaccharides
Other Lipids
Molecular Type
- Polymer-drug Conjugates, Dendrimers, Polypeptides
- Cationic/Ionizable Lipids, Peg-lipid, Phospholipids
- GalNAc Derivatives, Modified Monosaccharides, Synthetic Oligo[poly]saccharides
Technology
- Solid Phase and Liquid Phase Synthesis Technology Platform
- Combinate Downstream Technologies with prep-HPLC and Rp-prep-HPLC, Ionic Exchange, and TFF Technology
- Formulations Development and Manufacturing
- Comprehensive Analysis, Inspection and Quality Research
Service Scope
- mg-g Scale Sample Preparation for Pre-clinical Studies
- Process Development and Scale-up Mfg. (non-GMP & GMP)
- Analytical Method Development, Validation, and Stability Study
- IND/NDA CMC Dossier
Service Mode
Porton Sites
Minhang, Shanghai
- Area: 22000 m2
- For Mg-kg Scale Preparation, Process Development and Quality Research
- HP Area: Achieved OEB 5 (OEL < 0.05 μg/m3)
Fengxian, Shanghai
- Area: 64000 m2
- IND, GMP Clinical Batches and Commercial Manufacturing
- HP Area: Achieved OEB 5 (OEL < 0.05 μg/m3)
Liangjiang, Chongqing
- Area: 34000 m2
- 6 Drug Product GMP Workshops
- Liquid Injection：30 M units/year
- Lyophilized Powder：3.3 M units/year
Pudong, Shanghai
- Area: 5000+ m2
- Bioconjugation (10~200 L, OEB 5)
- Oral, Injectable
- Pre-clinical to Phase II
Case Studies
More
Biocatalysis Enables The Efficient Synthesis and Commercial Application of Unnatural Amino Acids (UAAs)
Biocatalysis is a pivotal enabler for the sustainable synthesis of unnatural amino acids. By integrating novel enzymes discovery, multi-enzyme cascades and chemo-enzymatic routes, Porton has established practical capabilities to address industry challenges in substrate specificity and enzyme stability. Moving forward, Porton remains dedicated to bridging the gap between laboratory innovation and industrial-scale application, providing customers with reliable, scalable and atom-efficient solutions for UAA production.
More
Dry Particle Coating for the Enhancement of API Flowability and Bulk Density
The mechanism of the dry particle coating and a short description of four coating techniques including comil, LabRAM, a high shear mixer and a jet mill are provided.
More
The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology
Adhering to Porton’s core value of “Pursuing Excellence”, Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.
More
Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients
Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.
More
Optimizing Process Chemistry for Enhanced Pharmaceutical Manufacturing
Process Chemistry Optimization | Pharma Manufacturing
More
Expert Q&A: How to Efficiently Apply Preparative Chromatography in Drug Research
How to Efficiently Apply Preparative Chromatography in Drug Research
More
Biocatalysis: A Powerful and Possible Greener Tool for Chemists in the Pharmaceutical Industry
End-to-end Enzyme Solutions Efficient Screening & process Development Comprehensive Quality Control Extensive Successful Applications Cases Technological Innovation Enabled Cost Savings
More
Expert Q&A: Molecular Simulation and Data Science Support of Porton
Explore virtual screening duration, differences from property optimization, and crystal structure requirements for impurity rejection calculations.
More
Selecting the Right Solid Form-Faster, Smarter, Better
At Porton J-Star, we employ an integrated approach to identify and select the most suitable solid form for development (Figure 2). We conduct effective screen and rigorous assessments for polymorphs, salts, cocrystals, as well as amorphous solid dispersions, by applying our comprehensive expertise and experience.
More
Preformulation Strategy- Inception to Completion
Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.
More
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
More
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
More
News
MoreNews2026-04-03
Porton & Pliant Joint Publication in ACS Catalysis
More
News2026-03-31
Porton Newsletter - March 2026 Recap
More
News2026-03-22
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
More
News2026-03-03
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
More
News2026-02-28
Porton Newsletter - February 2026 Recap
More
News2026-02-03
Porton Newsletter - January 2026 Recap
More
News2026-01-09
Porton Newsletter - Q4 2025 Recap
More
News2026-01-08
A Porton Publication in ACS Journal on Polymorphic Crystallization Kinetics Study and Control
More
News2025-12-30
Porton Achieves EU QP Certification for Chongqing Manufacturing Facility
More
News2025-11-27
Porton Pharma Solutions Ranks Among China's Top 100 Premier Pharmaceutical Suppliers and Top 10 in ESG Competitiveness
More
News2025-08-20
Porton Nominated for the 2025 Sedex Supply Chain Award
More
News2025-07-31
Porton and Repare Therapeutics Collaborate on OPRD Publication, Demonstrating Strength in Synthetic Process Development and Optimization
More
